Peripheral Arterial Disease Clinical Trial
— FREEDOM OPOfficial title:
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
Verified date | November 2019 |
Source | Nantes University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Over the past years, arterial closure systems have tended to replace manual compression to
ensure hemostasis at femoral artery puncture points. Arterial closure systems reduce
hemostasis and patient immobilization times, thus enabling early resumption of walking. These
devices have contributed extensively to the development of outpatient stays for cardiology,
vascular and neuro-radiology procedures.
According to certain studies however, it would appear that arterial closure devices do not
present any greater benefits than manual compression in terms of hemostasis and
complications. Moreover, the use of increasingly small diameter instruments would tend to
render manual compression sufficient. Finally, the use of these devices generates additional
costs.
The purpose of our prospective study is to evaluate the feasibility and safety of same-day
discharge after manual compression in patients treated for peripheral artery disease by
endovascular technique with 5F sheath.
Status | Completed |
Enrollment | 116 |
Est. completion date | October 10, 2019 |
Est. primary completion date | October 10, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age > 18 years, - Endovascular treatment by stent or drug coating balloon 5F and 0.035 compatible - Femoral approach - Outpatient hospitalization - Manual compression at puncture site - Rutherford 2 to 5 - Patient affiliated with a social security scheme - Patient's signed informed consent form Exclusion Criteria: - Under-age patient - Patient of age, but under legal guardianship or care - Contraindication to endovascular treatment - Use of a 6F or greater sheath - Radial or brachial puncture - Acute ischemia - Anticoagulant treatment or hemostasis disorder - Allergy to Elastoplast® type adhesive strips - Life expectancy of less than one month - Refusal of patient to participate in the study - Participation in another therapeutic trial - Pregnant woman, lactating women - Patients do not understand the French language or unfit for proposed follow in the study |
Country | Name | City | State |
---|---|---|---|
France | CHU de Besançon | Besançon | |
France | CHU de Bordeaux | Bordeaux | |
France | AP-HP, Hôpital Ambroise Paré | Boulogne-Billancourt | |
France | CHU de Clermont Ferrand | Clermont-Ferrand | |
France | CHU de DIJON | Dijon | |
France | Clinique de Fontaine-Les- Dijon | Dijon | |
France | Nantes University Hospital | Nantes | |
France | AP-HP, Hôpital Européen Georges Pompidou | Paris | |
France | Institut Mutualiste Montsouris | Paris | |
France | Clinique de l'Europe | Rouen |
Lead Sponsor | Collaborator |
---|---|
Nantes University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total in-hospital admission rate | Total in-hospital admission rate includes unplanned overnight surveillance and re-hospitalization rate at 1 month. | 1 month | |
Secondary | Death (all causes) at 1 month. | 1 month | ||
Secondary | Unplanned overnight surveillance rate | 1 month | ||
Secondary | Re-hospitalization after discharge during M1 | 1 month | ||
Secondary | Occurrence of major events during the perioperative period (H0 to M1) | Occurrence of major events during the perioperative period (H0 to M1) (MACE: Major Adverse Cardiovascular Event, MALE: Major Adverse Limb Event) | 1 month | |
Secondary | Occurrence of major punctured femoral artery events during the perioperative period (H0 to M1) | Occurrence of major punctured femoral artery events during the perioperative period (H0 to M1), requiring prolongation of hospitalization, repeat hospitalization or repeat surgery (hematoma, hemorrhage, false aneurysm, arterio-venous fistula, infection…). | 1 month | |
Secondary | Occurrence of minor punctured femoral artery events during the perioperative period (H0 to M1), not requiring prolongation of hospitalization, repeat hospitalization or repeat surgery | 1 month | ||
Secondary | Technical success which is defined successful vascular access and completion of the endovascular procedure and immediate morphological success with less than 30% residual diameter reduction of the treated lesion on completion angiography. | 1 month | ||
Secondary | Time for groin compression and dressing. | 1 month | ||
Secondary | Freedom from target lesion revascularization (TLR) at 1 month. | TLR expresses the frequency of the need for repeated procedures (endovascular or surgical) due to a problem arising from the treated lesion in surviving patients with preserved limb. | 1 month | |
Secondary | Freedom from target extremity revascularization (TER) at 1 month. TER is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target limb in surviving patients with preserved limb. | 1 month | ||
Secondary | Clinical success at 1 month. | Clinical success is defined by defined as a sustained upward shift of 1 category of the Rutherford classification for claudicants and by wound healing and rest pain resolution for patients in CLI, without the need for repeated TLR in surviving patients. | 1 month | |
Secondary | Haemodynamic improvement: of ABI-values with 0.10 as compared to baseline values or to ABI inferior or egal 0.9 at 1-month without need for repeated TLR in surviving patients. | 1 month | ||
Secondary | Quality of life evaluation (EQ5D-3L) at 1 month. | 1 month | ||
Secondary | Economic analysis endpoints | Resources consumed will be recorded from the intervention to one month post-operatively. We will collect hospital resources consumed (length of procedures, operative room staff, medical device used in case of manual compression's failure, hospitalizations due to complications…) and office-based care resources (medical and paramedical consultations, caregivers). | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |